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Background: In patients with severe calcific aortic stenosis, balloon aortic valvuloplasty (BAV) is routinely performed
in order to pre-dilate the stenosed aortic valve prior to transcatheter aortic valve implantation (TAVI). Although
pre-dilation is considered to be essential for the preparation of the valve landing zone, there is no clear evidence to
support its clinical value. In contrast, BAV has been suggested to be linked to several complications. Notably, while
preliminary evidence has supported the feasibility and safety of TAVI without pre-dilation, larger studies directly
comparing the benefit/risk profile of TAVI in the presence and absence of pre-dilation are required.
Methods/Design: Therefore, a prospective, two-armed, multicenter registry (EASE-IT) was designed to obtain essential
data concerning procedural success rates, adverse events, and mortality in a large cohort of patients undergoing
transapical (TA)-TAVI using the Edwards SAPIEN 3 balloon expandable heart valves with and without pre-ballooning.
Discussion: Data provided by EASE-IT will be used to assess the relevance of BAV during the TAVI procedure and to
investigate associations between patient characteristics and outcomes. Therefore, results obtained from the EASE-IT
registry could contribute to reduced rates of TAVI-associated morbidity and mortality in patients with severe, calcific
aortic stenosis.
Trial registration: ClinicalTrials.gov Identifier: NCT02127580
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Degenerative aortic stenosis (AS) is characterized by the
narrowing of the aortic heart valve and most frequently
is associated with progressive calcification and fibrosis of
the valve leaflets. It represents the most common form
of valve disease in the Western world and is associated
with an estimated 5-year survival rate of 32% in the ab-
sence of treatment [1-3]. Thus, severe symptomatic AS
constitutes a class I indication for aortic valve replace-
ment surgery [4]. In this regard, conventional surgery
has proven to be safe and effective for eligible patients
[5,6]. However, open heart surgery cannot be performed* Correspondence: peter.bramlage@ippmed.de
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unless otherwise stated.in 30–40% of patients due to advanced age and/or co-
morbidities [1,7]. For this reason, transcatheter aortic
valve implantation (TAVI), which was first described by
Cribier et al. [8,9], has emerged as a ground-breaking al-
ternative technique for valve delivery in elderly, mostly
fragile patients. Indeed, the TAVI approach has shown
similar efficacy as compared to surgery and survival ben-
efits in patients where surgery cannot be performed
(PARTNER) [10-12]. Since its introduction into clinical
use, continuous efforts have been undertaken to evaluate
and improve TAVI techniques with the objective of re-
ducing TAVI-associated complications.
Since the introduction of TAVI [8,9], pre-dilation of the
aortic valve has been considered as an obligatory step prior
to transcatheter heart valve (THV) placement. BAV is car-
ried out under rapid right ventricular pacing (>180 bpm)ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the aortic annulus and to enable full balloon-inflation for
3–5 seconds with the associated obstruction of the aortic
annulus. Potential advantages of performing BAV before
replacement of the aortic valve may be the following: sizing
evaluation when injecting above the inflated balloon,
checking the risk for coronary occlusion and supporting
evidence for coronary protection in selected cases, check-
ing for pacemaker capture in real-time, checking for “bal-
loon jump” in cases with LVOT obstruction or mitral
prosthesis, and checking the synchronization of operating
team [13]. Though, BAV has been suggested to be associ-
ated with the following serious complications [14-17]: (1)
hemodynamic failure such as prolonged hypotension, need
for cardiopulmonary reanimation, cardiac tamponade; (2)
arrhythmia requiring medical treatment or AV block with
need for pacing; (3) vascular events like systemic embolism
or myocardial infarction; and (4) bleeding due to cardiac
perforation, trauma-mediated aortic root rupture etc.
Therefore, due to these potentially life-threatening com-
plications, it has been suggested that removal of the
pre-dilation step might reduce the rates of adverse
events in patients undergoing TAVI [18-20].
So far, only preliminary studies have investigated the
clinical value of pre-dilation of stenosed aortic valves in
patients receiving self-expandable THVs through the trans-
femoral (TF) route [18,19] or balloon expandable valves via
the transapical (TA) route [20]. In a pilot study by Grube
et al., the feasibility and safety of TF-TAVI in the absence
of pre-dilation was studied using the self-expandable
Medtronic CoreValve (MCV) device in 60 consecutive pa-
tients within 13 centers [18]. A technical success rate of
96.7% was observed, with post-dilation required in 16.7%
of the cases and an in-hospital mortality rate of 6.7%. Thus,
the procedure was reported to display a safety and efficacy
profile that was similar to that of the standard approach
with dilation. In addition, Mendiz et al. conducted a study
of 51 patients undergoing TF-TAVI without pre-dilation
using the MCV device within a single center, observing a
procedural success rate of 94.2% and an in-hospital mortal-
ity rate of 3.9% [19]. However, only one pilot study involv-
ing six patients has examined TA delivery of balloon
expandable Edwards SAPIEN THVs in the absence of BAV
[20]. Successful deployment was observed in all patients
and elimination of the pre-dilation step was suggested to
result in shortened procedural duration, decreased radi-
ation exposure, and reduced usage of contrast agents. It
was also proposed that TA-TAVI without BAV might di-
minish the likelihood of hemodynamic instability in pa-
tients with impaired LVEF.
Although these preliminary investigations have started
to evaluate the safety of TAVI without pre-dilation, lar-
ger datasets directly comparing TAVI in the presence
and absence of BAV are required to fully assess the risksand/or benefits associated with elimination of the pre-
dilation step. For this reason, we have designed a prospect-
ive, two-armed, multicenter registry (EASE-IT) to compare
the safety and efficacy of TA-TAVI using Edwards SAPIEN
3 with and without pre-ballooning. EASE-IT aims to docu-
ment adverse events, mortality, and procedural data in
order to assess the importance of pre-dilation during TAVI
and to identify potential associations between patient char-
acteristics and outcomes.
Methods/Design of EASE-IT
EASE-IT is a multicenter, prospective, two-armed, obser-
vational registry. Enrollment of 200 subjects will take place
at up to 10 study-sites in Germany. Approval was obtained
by the Ethics Committee of the Landesärztekammer
Stuttgart on February 25th 2014 and confirmation ob-
tained at each site participating in ROUTE prior to pa-
tient enrollment. All patients are required to provide
written informed consent prior to participation. The in-
vestigation commenced in April 2014.
Site selection
Sites are selected based on prior experience with TA-
TAVI (i.e., minimum of 20 prior implantations) and the
ability to enroll a minimum of two patients per month.
All participating sites have been, independent of this
registry, trained in the use of the Edwards SAPIEN 3
and Ascendra Balloon Catheter according to the manufac-
turer’s instructions for use (Edwards Lifesciences, Irvine,
CA, USA) and by means of exhaustive fundamentals
training (i.e., didactic sessions, case observations, device
preparation, and simulator training). This will be followed
by on-site training as specified by the Edwards Standard
Operating Procedure.
Patient selection
Patient eligibility for EASE-IT will be based on the fol-
lowing criteria: (1) indication for TAVI in accordance
with the Edwards SAPIEN 3 instructions; (2) eligibility
for TAVI with and without BAV; and (3) at least 18 years
of age. Patients with contraindications based on instruc-
tions for use of either TAVI or the Ascendra Balloon
Catheter will be excluded from the study. Additionally,
patients meeting any of the following criteria will be
excluded: (1) logistic EuroSCORE I >50%; (2) mitral or
tricuspid valvular insufficiency (> grade II); (3) previous
aortic valve replacement; (4) uncontrolled atrial fibrilla-
tion; (5) left ventricular or atrial thrombus by echocardi-
ography; (6) recent cerebrovascular event (within the
last 3 months);and (7) high probability of non-adherence
to follow-up requirements (due to social, psychological,
or medical reasons). Each participating center must
document 10 consecutive cases with BAV and 10 cases
without BAV.
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Notably, TA-TAVI with pre-dilation is to be performed
as previously described by Walther et al. [13], whereas
the procedure without pre-dilation will be carried out in
a similar manner to that described by Wendler et al.
[20]. Pre-operation computed tomography will generally
be used for valve sizing purposes. However, investigators
can modify these procedures to fit their needs. Patients
will be assigned into groups (i.e., with BAV or without
BAV) by their physician prior to study enrollment and
independent of the registry.
Pre-defined objectives
The primary evaluation criteria at 1 month will consider
the combined endpoint of all-cause mortality, stroke, non-
fatal myocardial infarction, acute kidney injury, and pace-
maker implantation within 30 days after TAVI as to VARC2
(Figure 1). Secondarily, the rates of each of these individual
adverse events will be considered, along with duration of
radiation, amount of contrast agent, and aortic root rup-
ture. Six months after TAVI, the combined and separate ad-
verse events will once again be evaluated. Patient outcomes
will be compared between the two groups, with implant-
ation plus pre-dilation considered as the control arm.
Data collection
Patient data will be collected using electronic case report
forms (eCRFs), which must be signed electronically by in-
vestigators and/or designees (Table 1). The eCRFs should
be completed at the earliest opportunity. All registry doc-
uments will identify subjects by patient registry identifica-
tion numbers only (or initials when applicable).
A total of 20% of the sites (i.e., up to two sites) will be
selected at random for monitoring following completion
of patient follow-up and documentation. Source data
verification will be performed for all patients in these














Decision made by the
treating physician
prior to enrollment
Figure 1 Registry design.conducted for the following serious adverse events: death,
stroke, major bleeding, valve complications, vascular com-
plications, permanent pacemaker implantation, and renal
failure. For data analysis, linearized rates and actuarial
probability statistics will be used for adverse event report-
ing, and Kaplan-Meier analyses will be performed for sur-
vival and adverse event outcomes when appropriate.
Statistics
The sample size for EASE-IT was established based on
previously reported event rates and the feasibility to de-
tect an absolute risk reduction for the primary endpoint
of 13% at 30 days while taking into consideration a 10%
drop out rate [18,20]. Intention-to-treat analysis, based
on all patients enrolled in the registry will be performed.
Subjects are considered registry participants when they
enter the cath lab/hybrid suite. Descriptive data summar-
ies will be used to present and summarize the collected
evaluation data. For categorical variables (e.g. gender) fre-
quency distributions will be given. For numeric variables
(e.g. patient age) minimum, maximum, mean, median and
standard deviation will be calculated. Linearized rates and
actuarial probability statistics may be used where appro-
priate for adverse event reporting. Kaplan-Meier analysis
will be performed for survival outcomes and where appro-
priate for adverse event outcomes.
Discussion
EASE-IT represents a prospective, multicenter, two-armed
registry aimed at documenting the course of patients
undergoing TA-TAVI using the Edwards SAPIEN 3 with
or without pre-dilation via BAV. Information provided by
EASE-IT will be used to assess the value of pre-dilation
during TAVI procedures and to investigate associations
between patient characteristics and outcomes. Thus, re-
sults obtained from the EASE-IT registry should have sev-
eral important implications.6
ith pre-dilation (n=100) 
ithout pre-dilation (n=100) 
months
elective follow-up
Table 1 Data collection
Parameter Admission Intervention Discharge 30d FU 6 Mo FU
Inclusion/Exclusion criteria X
Demographics X
Diagnosis of valve disease X
Echocardiography X
Symptoms X X X




Prior cardiovascular intervention X
Current medications X X X X
Interventional details X
Interventional results X
AE X X X X
Hospitalization duration X
Creatinine value X X
Early safety/Clinical efficacy X X
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gested the feasibility and safety of performing TF-and TA-
TAVI without pre-dilation of the stenosed aortic valve
[18-20], these studies have not directly compared the out-
come of patients undergoing TAVI with and without pre-
dilation. Nevertheless, in the study by Grube et al. [18], 60
subjects undergoing TF-TAVI using the MCV device in
the absence of BAV were compared to a historical control
group (with BAV), suggesting that the efficacy of the sim-
plified procedure (i.e., without pre-dilation) was similar to
that of the standard approach. However, it is known that
this type of comparison can be associated with several
methodological limitations. Therefore, the conclusions by
Grube et al. must be appropriately verified. In addition,
data regarding delivery of the Edwards SAPIEN THV in
the absence of pre-dilation are extremely limited [20]. For
these reasons, EASE-IT has been designed to determine
whether BAV during TA-TAVI using the Edwards SA-
PIEN 3 yields relevant beneficial or negative procedural
effects based on a two-armed registry approach, which will
allow for direct comparison between the patient groups
(i.e., with BAV vs. without BAV). Thus, the comparative
analysis that can be performed from information collected
during the EASE-IT registry will be fundamental for es-
tablishing the importance of pre-dilation during TA-TAVI.
Notably, a recent imaging study suggested that new si-
lent cerebral lesions appear in approximately 90% of pa-
tients undergoing TAVI [21], with the highest number of
embolisms shown to occur at the time of pre-dilation
and valve deployment [22]. This is interesting consider-
ing that BAV has been suggested to cause thrombosis,which can result in coronary obstruction, myocardial in-
farction, or stroke [16]. In addition, BAV has been linked
to transient ischemia (coronary, cerebral, and renal), aor-
tic root rupture, as well as hemodynamic failure and/or
systemic inflammation in patients with reduced LVEF
[14-16,23]. With regard to these BAV-related complica-
tions, EASE-IT should yield important information con-
cerning the benefit of pre-dilation during TAVI. Indeed, if
the results of EASE-IT demonstrate that BAV during TA-
TAVI is unnecessary or detrimental, then these risks could
be avoided altogether by elimination of the pre-dilation
step. On the other hand, if BAV is found to contribute to
procedural success, then exposure to these potential BAV-
associated risk factors may be warranted. Also, it is pos-
sible that BAV will yield differential benefits or procedural
risks within distinct populations (e.g., detrimental for pa-
tients with reduced LVEF). For this reason, EASE-IT will
also examine associations between patient characteristics
and outcomes. Thus, results obtained from the EASE-IT
registry have the potential to promote evolution of the
TAVI procedure in order to reduce the risk of microem-
bolization, stroke, and other severe complications in pa-
tients with AS.
Regarding exclusion of the pre-dilation step during
TAVI, the resulting simplified approach might reduce
the procedural time, amount of contrast agent used, and
duration of fluoroscopy as indicated by Wendler et al.
[20]. In this regard, as part of the secondary evaluation cri-
teria in EASE-IT, information related to these procedural
factors will be recorded for analysis. Indeed, the simplified
approach would also eliminate the delay between pre-
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during which patients can become hemodynamically un-
stable. Thus, removal of the pre-dilation step has been
suggested to be ideal for avoiding complications in pa-
tients with severely impaired LVEF [20]. Nevertheless,
additional risks may be associated with implantation of
the valve in the absence of pre-dilation, such as the poten-
tial need for post-procedural dilation, which was found to
be required in 16.7% of subjects in the absence of BAV by
Grube et al. [18]. Thus, EASE-IT will be important for
analyzing the potential benefits or disadvantages associ-
ated with altering procedural factors during the simplified
TAVI approach.
Furthermore, results obtained by EASE-IT regarding
the importance of pre-dilation during TAVI might only
be applicable to the Edwards SAPIEN 3, and not other
commercially available devices. In this regard, another
ongoing prospective, randomized trial has been initiated
by a group at Bonn University (NCT01539746; Trans-
catheter Aortic Valve Implantation Without Pre-dilation
[SIMPLIFy TAVI]) in order to investigate the 30-day com-
posite endpoint in patients with severely impaired LVEF
(≤35%) undergoing TAVI using MCV devices. Therefore,
EASE-IT registry results, which are likely to be reported
after completion of the SIMPLIFy TAVI trial (scheduled
to end December 2014), should hold particular signifi-
cance with regard to the generalizability of the impact of
BAV on TAVI outcome as related to distinct devices and
populations. Indeed, studies testing the importance of the
pre-dilation step will need to be carried out for specific
delivery systems, routes, and patient populations in order
to conclusively determine whether the use of BAV is
beneficial. Therefore, EASE-IT will be essential for con-
tributing to the body of data necessary for establishing
the value or risk associated with pre-dilation procedures
during TAVI.
Potential limitations of EASE-IT
Although EASE-IT represents a critical step for examin-
ing the importance of performing pre-dilation during
TAVI procedures involving Edwards SAPIEN 3, the study
might display limitations related to its design. Indeed, the
non-randomized nature of the registry could lead to po-
tential bias, as investigators will assign patients into the
“with BAV” and “without BAV” groups at their discretion
while patients are eligible for either route. In addition, be-
cause we ask for patients eligible in principal for TAVI
with AND without BAV we will miss those only eligible
for one of the routes. This cannot be avoided, however, if
we want to compare both techniques in one patient popu-
lation. We have chosen to use the observational design be-
cause we only incompletely know the variables affecting
the decision and are thus not able, without a pilot docu-
mentation like the present one, to properly assess thevariables necessary for the decision and these might de-
serve a prospective assessment in an upcoming random-
ized controlled trials.
Nevertheless, inclusion into the EASE-IT trial requires
that patients be eligible for TAVI with and without BAV,
which could alleviate the potential for bias. In addition,
registry data tend to be less complete when compared to
randomized clinical trials. However, in this regard, 20%
of the sites will be randomly selected for monitoring
following completion of patient follow-up and documen-
tation. Source data verification will be performed for all
patients in these centers. Moreover, it is possible that
the 6-month follow-up will not be sufficient to detect
differences in long-term adverse outcomes between the
groups with and without pre-dilation. Thus, future ran-
domized clinical trials may be needed in order to assess
the long-term effects associated with eliminating BAV
from the TA-TAVI procedure.
Conclusions
The EASE-IT registry will provide essential data concern-
ing procedural success rates, adverse effects, and mortality
in a large cohort of patients undergoing TA-TAVI with
and without pre-dilation. This information is essential for
determining the benefits or complications that might be
associated with the pre-dilation step during TAVI. There-
fore, results obtained from EASE-IT could contribute to
reducing rates of TAVI-associated morbidity and mortality
in patients with severe AS.
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